Patient characteristics
| . | All PSMA-PET patients (N = 200) . | PSADT of ≤10 months (n = 115) . | Gleason score ≥8 only (n = 85) . | SPARTAN (N = 1,207) . |
|---|---|---|---|---|
| Age (years) | ||||
| Median (range) | 71 (46–94) | 71 (46–94) | 73 (48–86) | 74 (48–97) |
| Prostate-specific antigen (ng/mL) | ||||
| Median (range) | 5.3 (1.3a–263.8) | 5.2 (1.3a–263.8) | 5.4 (2.0–99.1) | 7.8 (0.1–294.8) |
| Prostate-specific antigen doubling time (months) | n = 132 | n = 17 | ||
| Median (range) | 4.0 (0.0–90.0) | 3.6 (0.0–10.0) | Not applicable | 4.4 (0.7–10.0) |
| ≤6 | 85 (64) | 85 (74) | Unknown | 860 (71) |
| >6 | 47 (36) | 30 (26) | 17 (100) | 347 (29) |
| Gleason score | n = 193 | n = 108 | n = 1171 | |
| <8 | 42 (22) | 42 (39) | 0 (0) | 661 (56) |
| ≥8 | 151 (78) | 66 (61) | 85 (100) | 510 (44) |
| Prior therapy | ||||
| Prior prostate cancer–related surgery | 130 (65) | 79 (69) | 51 (60) | 682 (57) |
| Prior prostate cancer–related radiotherapy | 104 (52) | 69 (60) | 35 (41) | 696 (58) |
| . | All PSMA-PET patients (N = 200) . | PSADT of ≤10 months (n = 115) . | Gleason score ≥8 only (n = 85) . | SPARTAN (N = 1,207) . |
|---|---|---|---|---|
| Age (years) | ||||
| Median (range) | 71 (46–94) | 71 (46–94) | 73 (48–86) | 74 (48–97) |
| Prostate-specific antigen (ng/mL) | ||||
| Median (range) | 5.3 (1.3a–263.8) | 5.2 (1.3a–263.8) | 5.4 (2.0–99.1) | 7.8 (0.1–294.8) |
| Prostate-specific antigen doubling time (months) | n = 132 | n = 17 | ||
| Median (range) | 4.0 (0.0–90.0) | 3.6 (0.0–10.0) | Not applicable | 4.4 (0.7–10.0) |
| ≤6 | 85 (64) | 85 (74) | Unknown | 860 (71) |
| >6 | 47 (36) | 30 (26) | 17 (100) | 347 (29) |
| Gleason score | n = 193 | n = 108 | n = 1171 | |
| <8 | 42 (22) | 42 (39) | 0 (0) | 661 (56) |
| ≥8 | 151 (78) | 66 (61) | 85 (100) | 510 (44) |
| Prior therapy | ||||
| Prior prostate cancer–related surgery | 130 (65) | 79 (69) | 51 (60) | 682 (57) |
| Prior prostate cancer–related radiotherapy | 104 (52) | 69 (60) | 35 (41) | 696 (58) |
NOTE: Data are number of patients (%) unless otherwise indicated.
aTwo eligible patients had prostate-specific antigen ≤2 ng/mL at time of PSMA-PET.